Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program

por Wharton, Sean, Haase, Christiane L, Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca AG
Publicado 2020

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada

por Wharton, Sean, Liu, Aiden, Pakseresht, Arash, Nørtoft, Emil, Haase, Christiane L., Mancini, Johanna, Power, G. Sarah, Vanderlelie, Sarah, Christensen, Rebecca A. G.
Publicado 2019

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

por Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Publicado 2020

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)

por Davies, Melanie, Færch, Louise, Jeppesen, Ole K, Pakseresht, Arash, Pedersen, Sue D, Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A, Lingvay, Ildiko
Publicado 2021

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)

por Rahman, Syed Kasfur, Davies, Melanie, Færch, Louise, Jeppesen, Ole K, Pakseresht, Arash, Pedersen, Sue D, Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A, Lingvay, Ildiko
Publicado 2022

Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study

por Sharma, Arya M., Bélanger, André, Carson, Veronica, Krah, Jodi, Langlois, Marie‐France, Lawlor, Diana, Lepage, Suzanne, Liu, Aiden, Macklin, David A., MacKay, Noel, Pakseresht, Arash, Pedersen, Sue D., Ramos Salas, Ximena, Vallis, Michael
Publicado 2019